^
Association details:
| Biomarker: | PIK3CA E545K |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | risovalisib (CYH33) (PIK3CA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
33O A phase I study to evaluate safety, pharmacokinetics (PK), and preliminary efficacy of CYH33, a phosphatidylinositol 3-kinase a (PI3Ka) inhibitor, in patients (pts) with advanced solid tumours
Published date:
03/01/2021
Excerpt:
Other 3 pts with partial response (PR) were found in 1 OC pt (PIK3CA E545K mutation), 1 BC pt (PIK3CA E545K mutation), and 1 gastric cancer (PIK3CA E542K mutation)....CYH33 demonstrates a manageable safety profile and linear pharmacokinetic characteristics.
DOI:
https://doi.org/10.1016/j.annonc.2021.01.048
Trial ID:
